Effect of ciclesonide on quality of life in patients with moderate persistent asthma (21 to 65 y) (BY9010/AR-101)

Study identifier:BY9010/AR-101

ClinicalTrials.gov identifier:NCT00305461

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A pilot study on the impact of two different doses of ciclesonide (160 mcg/day and 320 mcg/day) administered in the evening on Quality of Life in patients with moderate persistent asthma.

Medical condition

asthma

Phase

Phase 3

Healthy volunteers

No

Study drug

Ciclesonide

Sex

All

Actual Enrollment

101

Study type

Interventional

Age

21 Years - 65 Years

Date

Study Start Date: 01 Feb 2006
Primary Completion Date: 01 Mar 2007
Study Completion Date: 01 Feb 2008

Study design

Allocation: Randomized
Endpoint Classification: None
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment

Verification:

Verified 01 Sept 2016 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria